|
EQS-News: Eckert & Ziegler SE / Key word(s): 9 Month figures Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024 14.11.2024 / 07:45 CET/CEST The issuer is solely responsible for the content of this announcement. Berlin, November 14, 2024. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales by 17% year-on-year to € 215.5 million in the first nine months of 2024. Recurring EBIT from continuing operations (adjusted EBIT) rose by 24% to € 46.7 million. Net income (from continuing and discontinued operations) grew by 15% and reached € 23.4 million or € 1.12 per share. The Medical segment recorded sales of € 104.5 million in the first nine months of the year, around € 21.7 million or 26% higher than in the previous year. The main growth driver remains the pharmaceutical radioisotope business, while all other main product groups also increased compared to the previous year. The Isotope Products segment generated sales of € 111.0 million, an increase of € 10.0 million or 10% compared to the first nine months of 2023. In comparison to the same period of the previous year, seasonal effects and shifts between product groups continued to move towards higher-margin products. For the 2024 financial year, the Executive Board continues to expect revenues of around € 265 million and an EBIT (earnings before interest and taxes) before special items from continuing operations of around € 55 million. The complete quarterly report can be viewed here: https://www.ezag.com/q32024en/ About Eckert & Ziegler. Your contact: 14.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
A second Roche obesity drug shows promise in early studies
LONDON — Roche on Wednesday reported positive early data from another of the obesity drug candidates that it picked up through an acquisition late last
July 17, 2024